Huntington’s Disease Treatment Market Share

Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users. 

Huntington’s Disease Treatment Drug Type Insights

On basis of drug type the Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.

Huntington’s Disease Treatment Regional  Insights

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Huntington’s Disease Treatment Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injury market.  The European Huntington’s Disease Treatment industry has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Global Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market of huntington’s disease treatment in the Middle East & Africa has been segmented into the Middle East and Africa.

Global Huntington’s Disease Treatment Market Share (%), by Region, 2017

Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon

Geographically, the America holds the highest market share for huntington’s disease treatment market and the reason being many market players are engaged in development of new drug product innovation. According to the survey carried out by one of the University of Sheffield, the estimated prevalence of huntington’s disease in North America, North Western Europe and Australia ranges from 5.96 to 13.7 cases per 100 000 population.

Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of targeted population, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. 

The prevalence of huntington’s disease is significantly lower in Asian populations compared to Western Europe, North America and Australia.

The market in the Middle East & Africa is likely to account for the smallest share of the global huntington’s disease treatment.

Huntington’s Disease Treatment Market Key players

Some of the key players in the Market are 

• lnylam Pharmaceuticals Inc.


• AmpliPhi Biosciences Cor


• Ceregene Inc.


• Lundbeck


• Prana Biotechnology Limited


• Teva Pharmaceutical Industries Ltd.


• Cortex Pharmaceuticals Inc


• Vertex Pharmaceuticals Incorporated


• Auspex Pharmaceuticals


• SOM Biotech


• GlaxoSmithKline


• Siena Biotech, Raptor Pharmaceutical


• Pfizer


• Palobiofarma


• Omeros Ipsen


• Valeant Pharmaceuticals International Inc.

Huntington’s Disease Treatment Market Segmentation

Huntington’s Disease Treatment Drug Type Outlook

•      Tetrabenazine


•      Deutetrabenazine


•      Selective Serotonin Reuptake Inhibitor (SSRI)


•      Chlorpromazine


•      Haloperidol


•      Risperidone


•      Olanzapine


•      Clozapine


•      Other

Huntington’s Disease Treatment Treatment Outlook

•      Symptomatic Therapy


•      Disease-Modifying Therapy

Huntington’s Disease Treatment End-Users Outlook

•       Hospital


•       Clinics


•       Online Pharmacies


•       Retail Pharmacies


•       Others

Huntington’s Disease Treatment Region Outlook

• Americas
  
  
  
  •  North America
    
    
    
    •     US
    
    
    •     Canada
    
    
    
    
  
  
  •  South America
  
  
  
  


• Europe
  
  
  
  •  Western Europe
    
    
    
    •   Germany
    
    
    •     France
    
    
    •   Italy
    
    
    •   Spain
    
    
    •   UK
    
    
    •   Rest of Western Europe
    
    
    
    
  
  
  •  Eastern Europe
  
  
  
  


• Asia Pacific
  
  
  
  •   Japan
  
  
  •   China
  
  
  •  India
  
  
  • Australia  
  
  
  • Republic of Korea 
  
  
  • Rest of Asia Pacific 
  
  
  
  


• The Middle East & Africa
  
  
  
  •   Middle East
  
  
  •   Africa
  
  
  
  

Recent Development

The major players, such as Neurocrine Bioscience, Inc. and Azevan Pharmaceuticals, Inc. are concentrating on research and improvement of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an innovative drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a medicine that does its work by blocking vasopressin 1 a receptor in the brain. However, presently approved medicines give symptomatic and palliative care and do not target the fundamental cause of the disease. In addition, medications can reduce the seriousness of symptoms, they are often connected with unfavorable effects such as somnolence, gait issues, dysphagia, and apathy, which can have adverse impacts on a patient’s quality of life. Given the inefficiency of a cure for the disease, it is censorious to evaluate how health-related quality of life is affected in these patients.

Intended Audience:

• 
  
  
  
  • Manufacturers and Suppliers
  
  
  • Hospitals and Clinics
  
  
  • Laboratories and Associations
  
  
  • Research and Development (R&D) Companies
  
  
  • Government research institutes
  
  
  • Academic institutes and universities